Page 101 - Adt News Today

Former Union Agriculture Minister Sharad Pawar while addressing the press in Pune on Thursday said this course is the result of increased cooperation between ADT, University of Oxford and Microsoft’ farmvibes platform.

Explore Holders Technology Company Regulatory News (RNS) and non regulatory news updates for the latest insights on their financial performance, stock market status, and corporate governance. Stay informed about Holders Technology share price and industry developments. If you're an investor tracking the latest RNS announcements for Holders Technology or just want to find out what has happened to Holders Technology share price as it happens.

Equities researchers at Guggenheim began coverage on shares of Dynatrace (NYSE:DT – Get Free Report) in a research report issued on Monday, Briefing.com reports. The brokerage set a “buy” rating and a $58.00 price target on the stock. Guggenheim’s price objective indicates a potential upside of 25.22% from the stock’s current price. Several other equities […]

Automaker Honda remained the biggest foreign taxpayer in Vietnam in 2022, according to the General Department of Taxation’s latest list of the top 1,000 contributors of corporate income tax (CIT).

Kevin Kayvan Zarrabi, MD, MS, FACP, discusses the emergence of triplet therapy of ADT, AR-targeted therapy, and cytotoxic chemotherapy for patients with mHSPC; highlights key trials that have explored and supported the use of these triplets; and expands on the unanswered questions that remain regarding patient selection and chemotherapy eligibility.

It’s illegal for companies to make an offer to their existing clients — one they call a “value add” but which comes at an extra cost, of course — and then regard their lack of response as a yes.

DA Davidson upgraded shares of Dynatrace (NYSE:DT – Free Report) from a neutral rating to a buy rating in a research report sent to investors on Wednesday, Marketbeat reports. DA Davidson currently has $65.00 price target on the stock, up from their prior price target of $50.00. Other research analysts have also recently issued reports […]

Here we discuss some reasons why investing in CRISPR Therapeutics (CRSP) stock now may turn out to be a more prudent move than ever.

A comprehensive review of treatment options for patients with metastatic hormone-sensitive prostate cancer.

Alicia Morgans, MD, MPH, discusses androgen deprivation therapy and its role in treating prostate cancer.